Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Designing a Prevention Trial for Alzheimer Disease Using Lecanemab: The AHEAD 3-45 Study

Summary by neurologylive.com
The AHEAD 3-45 Study is currently assessing lecanemab asymptomatic stage of Alzheimer disease to assess whether the therapy can slow biomarker changes or cognitive decline at the earliest phases.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

neurologylive.comneurologylive.com

Designing a Prevention Trial for Alzheimer Disease Using Lecanemab: The AHEAD 3-45 Study

The AHEAD 3-45 Study is currently assessing lecanemab asymptomatic stage of Alzheimer disease to assess whether the therapy can slow biomarker changes or cognitive decline at the earliest phases.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

neurologylive.com broke the news in on Friday, July 25, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal